|
gptkbp:instance_of
|
gptkb:drug
|
|
gptkbp:activities
|
inhibits microtubule depolymerization
|
|
gptkbp:appointed_by
|
intravenous infusion
|
|
gptkbp:approves
|
gptkb:1992
gptkb:FDA
|
|
gptkbp:brand
|
gptkb:Abraxane
gptkb:Taxol
|
|
gptkbp:can_be_used_with
|
gptkb:cisplatin
gptkb:carboplatin
gptkb:doxorubicin
|
|
gptkbp:case_types
|
gptkb:healthcare_organization
ovarian cancer
|
|
gptkbp:clinical_trial
|
Phase II
Phase III
Phase I
|
|
gptkbp:contraindication
|
neutropenia
severe hypersensitivity
|
|
gptkbp:developed_by
|
gptkb:Pacific_yew_tree
|
|
gptkbp:discovered_by
|
1960s
|
|
gptkbp:dissolved
|
soluble in organic solvents
poorly soluble in water
|
|
gptkbp:excretion
|
bile
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
paclitaxel
|
|
gptkbp:ingredients
|
C47 H51 N O14
|
|
gptkbp:invention
|
patented
generic available
|
|
gptkbp:is_a_source_of
|
natural product
semi-synthetic
|
|
gptkbp:is_atype_of
|
L01 C D01
|
|
gptkbp:is_used_for
|
treating cancer
|
|
gptkbp:lifespan
|
13 to 52 hours
|
|
gptkbp:manager
|
intravenous
oral (in some formulations)
|
|
gptkbp:marketed_as
|
gptkb:Bristol-Myers_Squibb
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:name
|
Essential Medicines
|
|
gptkbp:research
|
effective in combination therapies
improves survival rates in certain cancers
resistance development in some tumors
|
|
gptkbp:research_areas
|
drug development
oncology
pharmacology
|
|
gptkbp:safety_features
|
Category D (risk to fetus)
|
|
gptkbp:scientific_name
|
gptkb:paclitaxel
|
|
gptkbp:side_effect
|
fatigue
nausea
hair loss
neuropathy
|
|
gptkbp:weight
|
853.9 g/mol
|
|
gptkbp:bfsParent
|
gptkb:Athenex's_intravenous_paclitaxel
gptkb:Athenex's_oral_paclitaxel
|
|
gptkbp:bfsLayer
|
4
|